Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?
VIR-7831 Suffers Setback In NIH Study
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.